Bind Therapeutics Inc, Noble Energy, Inc., Others Are Moving After-Hours
Bind Therapeutics Inc (NASDAQ: BIND) gained 10 percent in late trading Thursday to $6.07 a share, after the company said its cancer drug development collaboration with Pfizer Inc. (NYSE: PFE) will be extended through March 2016.
Bind may get up to $88.5 million, plus additional commercial payments if the work is successful.
Scientific Games Corp (NASDAQ: SGMS) picked up 3 percent to $11.38 in the extended session. The casino equipment and services provider with Ronald O. Perelman as chairman didn't issue news.
Sucampo Pharmaceuticals Inc. (NASDAQ: SCMP) shares rose 3 percent after hours Thursday to $16.05 on no news.
Five Prime Therapeutics Inc (NASDAQ: FPRX) bounced up nearly 3 percent in late trading to $9.20, after closing down more than 7 percent. The company said Wednesday that it obtained $6.6 million in development funding for an HIV drug from the National Institutes of Health.
ImmunoGen, Inc. (NASDAQ: IMGN) gained 2 percent to $9.59 in the extended session Thursday after closing up more than 5 percent. The company on Wednesday named a new chief medical officer.
Eldorado Resorts Inc (NASDAQ: ERI) plunged 10 percent after hours Thursday to $4.73 after it said it will spend $5.1 million upgrading its casino in Erie, Pennsylvania.
ICICI Bank Ltd (NYSE: IBN) shares fell more than 5 percent in late trading to $10.13. The Mumbai-based financial services company didn't issue news.
Noble Energy, Inc. (NYSE: NBL) slipped 4.6 percent to $47.61 following the bell. An unconfirmed report surfaced Thursday that the company will lay off "dozens" of employees in Israel.
Verastem Inc (NASDAQ: VSTM) fell 4 percent in the extended session to $9.62. The cancer drug development company hasn't issued recent news but is off more than 17 percent this week as of Thursday's closing.
Genworth Financial Inc (NYSE: GNW) gave back 2 percent in late trading, changing hands at $7.60 a share. The stock had closed up more than 5 percent on a Bloomberg report that Genworth might sell its life and annuity business.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.